LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

1 result(s)
Filter and sort
1 result(s)
Journal Article > ResearchFull Text

HIV-associated Kaposi's sarcoma in Maputo, Mozambique: outcomes in a specialized treatment center, 2010-2015

Infect Agent Cancer. 19 January 2018; Volume 13 (Issue 1); DOI:10.1186/s13027-018-0177-6
Fardhdiani V, Molfino L, Zamudio AG, Manuel R, Luciano G,  et al.
Infect Agent Cancer. 19 January 2018; Volume 13 (Issue 1); DOI:10.1186/s13027-018-0177-6
Kaposi's sarcoma (KS) is a common HIV-associated malignancy associated with disability, pain and poor outcomes. The cornerstone of its treatment is antiretroviral therapy, but advanced disease necessitates the addition of chemotherapy. In high-income settings, this often consists of liposomal anthracyclines, but in Mozambique, the first line includes conventional doxorubicin, bleomycin and vincristine, which is poorly-tolerated. Médecins Sans Frontières supports the Ministry of Health (MOH) in a specialized HIV and KS treatment center at the Centro de Referencia de Alto Maé in Maputo.More